Accuray Europe

Accuray Showcases Radiation Therapy Innovations Designed to Improve What's Possible for Patients at ASTRO 2018

Sunnyvale, California (ots/PRNewswire) - Building on its heritage of patient-first innovation, at this year's ASTRO (American Society for Radiation Oncology) Annual Meeting, Accuray Incorporated (NASDAQ: ARAY) will showcase radiation therapy solutions designed to enable clinicians to deliver truly personalized cancer treatments aligned to the needs of each patient. Meeting attendees can visit Accuray at booth #2511 on October 21 - 23, 2018 in San Antonio, Texas to learn how advances in Accuray radiation therapy delivery systems and software are making it easier and faster to provide extremely precise results for the full range of cancer cases, from initial treatment to adaptive therapy to retreatments.

(Logo: https://mma.prnewswire.com/media/320376/accuray_incorporated_logo.jpg )

"We are proud to have the opportunity to attend this important meeting and provide access to information, demonstrations and educational opportunities for learning about advances in Accuray technologies. We are committed to partnering with the radiation oncology community to develop innovative products that will improve patient care, now and into the future," said Lionel Hadjadjeba, M.D., Senior Vice President, and Chief Commercial Officer at Accuray.

Meeting Highlights

New products and upcoming developments

- CyberKnife® VOLO(TM) Optimizer: This next-generation optimizer 
  simplifies the process of creating treatment plans, improves plan 
  quality and enables more efficient exploration of the tradeoffs 
  between treatment time and plan quality. Preliminary data from 
  Accuray indicates that the CyberKnife VOLO Optimizer will provide a
  significant reduction in optimization time, and up to 50 percent 
  reduction in treatment delivery time. Accuray will be launching 
  this new optimizer at its booth at 11:00 am on Sunday, October 21st
- CTrue(TM) IR (Iterative Reconstruction) for the Radixact® System: 
  This powerful IR software improves soft-tissue contrast and reduces
  noise, enhancing image quality, while maintaining the same low 
  imaging dose and fast reconstruction time as earlier versions of 
  the software. These enhancements enable clinicians to efficiently 
  deliver precise treatments more quickly, for more patients.
- Radixact System with Real-Time Motion Synchronization* [510(k) 
  pending, not available for sale]: Capabilities of the Radixact 
  System are being expanded to offer real-time motion 
  synchronization, with the goal of improving dose accuracy and 
  treatment times compared to other methods, such as gating. These 
  capabilities will build on the current Radixact System, which is 
  fully integrated with the Accuray Precision® Treatment Planning 
  System and iDMS(TM) Data Management System. These hardware and 
  software solutions work seamlessly together and were introduced to 
  help improve treatment outcomes and workflow efficiencies, enabling
  clinicians to provide optimal treatments for more patients, every 
  day. *Not 510(k) cleared or available for commercial distribution 

Events

Accuray will host two educational symposia and a broad range of Accuray Exchange in Radiation Oncology (AERO(TM)) Academy sessions. ASTRO meeting attendees will have the chance to learn from industry experts about clinical advances and best practices that have the potential to improve cancer patients' outcomes and quality of life.

Click here (https://accurayexchange.com/news-events/events/09-07-2018/astro-accuray-symposium-2018) for more information or to register for the symposia.

Symposia: Breast Cancer: Your Challenges Today - Our Solutions for Tomorrow:

Sunday, October 21st from 12:15p.m. - 1:15p.m.

- Moderator: Jean-Philippe Pignol, M.D., Ph.D. FRCPC; Dalhousie 
  University, Halifax, Canada
- Panelists  - Asal Shoushtari Rahimi, M.D., MS; U.T. Southwestern 
  Medical
  Center, Dallas, TX, USA
  - Nathan Corradini, MS, DABR SSRMP; Clinica Luganese, Lugano,
  Switzerland
  - Jennifer R. Bellon, M.D.; Dana-Farber Cancer Institute, Boston,
  MA, USA
  - Carole Massabeau, M.D.; Institut Universitaire du Cancer de
  Toulouse Oncopole, Toulouse, France  

Symposia: Dynamic Tracking and Motion Correction: Over 15 Years of Accuray Leadership:

Monday, October 22nd from 12:30p.m. - 1:30p.m.

- Moderator: Fabienne Hirigoyenberry-Lanson, P.hD., Vice President 
  Global Medical and Scientific Affairs, Accuray
- Panelists  - Cristian Cotrutz, Ph.D.; Swedish Radiosurgery Center, 
  Seattle, WA,
  USA
  - Jonathan W. Lischalk, M.D.; Medstar Georgetown University
  Hospital, Washington, DC, USA
  - John Bayouth, Ph.D.; University of Wisconsin School of Medicine
  and Public Health, Madison, WI, USA  

AERO(TM) Academy Sessions: October 21st - October 23rd

Attendees at this year's ASTRO meeting will have the opportunity to participate in interactive discussions with clinical experts on the use of Accuray technologies during daily presentations at Accuray booth #2511. Topics include building a CyberKnife® prostate SBRT practice; benefits of TomoDirect(TM) for breast cancer; interactive planning on the CyberKnife System with the new VOLO(TM) Optimizer; demonstration of PreciseRTX(TM) Retreatment Option; and plan adaptation with improved MVCT on the Radixact® System.

Unique Hologram Technology

Throughout the ASTRO meeting attendees will have the opportunity to view viRTual-Where Art Meets Science, an immersive virtual reality experience that provides an opportunity to see how Accuray patient-first innovations are transforming what is possible for cancer patients around the world.

About Accuray

Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.

Safe Harbor

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and outcomes, the availability and effectiveness of new product enhancements and releases, and Accuray's leadership position in radiation oncology innovation and technologies. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product offerings; the company's ability to develop new products or enhance existing products to meet customers' needs; delays in the development or release of new offerings; the company's limited long-term clinical data supporting the safety and efficacy of its products for certain users and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 24, 2018 and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Contact:

Accuray
Sancie Nakarat
+33-6-81-36-84-34
snakarat@accuray.com



Weitere Meldungen: Accuray Europe

Das könnte Sie auch interessieren: